Cancer Database Query Results

Scientific Papers found: Click to Expand⟱
2224- SK,    Shikonin induces apoptosis and autophagy via downregulation of pyrroline-5-carboxylate reductase1 in hepatocellular carcinoma cells
- in-vitro, HCC, SMMC-7721 cell - in-vitro, HCC, HUH7 - in-vitro, HCC, HepG2
PYCR1↓, PI3K↓, Akt↓, mTOR↓, eff↑,
2223- SK,    Non-metabolic enzyme function of PKM2 in hepatocellular carcinoma: A review
- in-vitro, Var, NA
PKM2↓,
2222- SK,    The anti-tumor effect of shikonin on osteosarcoma by inducing RIP1 and RIP3 dependent necroptosis
- in-vitro, OS, U2OS - in-vitro, OS, 143B - in-vivo, NA, NA
Necroptosis↑, RIP1↑, RIP3↑, OS↑, P53↑,
2221- SK,    Shikonin Induces Apoptosis, Necrosis, and Premature Senescence of Human A549 Lung Cancer Cells through Upregulation of p53 Expression
- in-vitro, Lung, A549
Apoptosis↑, TumCP↓, tumCV↓, Necroptosis↑, P53↑, ROS↑, NF-kB↓,
2220- SK,    Shikonin Alleviates Gentamicin-Induced Renal Injury in Rats by Targeting Renal Endocytosis, SIRT1/Nrf2/HO-1, TLR-4/NF-κB/MAPK, and PI3K/Akt Cascades
- in-vivo, Nor, NA
*RenoP↑, *ROS↓, *SIRT1↓, *NRF2↑, *HO-1↑, *GSH↑, *TAC↑, *SOD↑, *MDA↓, *NO↓, *iNOS↓, *NHE3↑, *PI3K↑,
2219- SK,    Shikonin induces apoptosis of HaCaT cells via the mitochondrial, Erk and Akt pathways
- in-vitro, Nor, HaCaT
*MMP↓, *ROS↑, *Casp3↑, *TumCG↓,
2217- SK,    Shikonin Inhibits Endoplasmic Reticulum Stress-Induced Apoptosis to Attenuate Renal Ischemia/Reperfusion Injury by Activating the Sirt1/Nrf2/HO-1 Pathway
- in-vivo, Nor, NA - in-vitro, Nor, HK-2
*ER Stress↓, *SIRT1↑, *NRF2↑, *HO-1↑, *eff↓, *RenoP↑, *GRP78/BiP↓, *CHOP/DDIT3↓, *Casp12↓, *BAX↓, *cl‑Casp3↓,
2216- SK,    Shikonin upregulates the expression of drug-metabolizing enzymes and drug transporters in primary rat hepatocytes
- in-vivo, Nor, NA
*NRF2↑, *AhR↑, *CYP1A1↑, *CYP1A2↑, *CYP2C6↑, *CYP2D1↑, *CYP3A2↑, *NQO1↑,
2215- SK,  doxoR,    Shikonin alleviates doxorubicin-induced cardiotoxicity via Mst1/Nrf2 pathway in mice
- in-vivo, Nor, NA
*cardioP↑, *ROS↓, *Inflam↓, *Mst1↓, *NRF2↑, *eff↓, *antiOx↑, *SOD↑, *GSH↑, *TNF-α↓, BAX↓, Bcl-2↑,
2214- SK,    Shikonin Attenuates Cochlear Spiral Ganglion Neuron Degeneration by Activating Nrf2-ARE Signaling Pathway
- in-vitro, Nor, NA
*NRF2↑, *HO-1↑, *NQO1↑, *antiOx↑, *neuroP↑, *ROS↓, *MDA↓, *SOD↑, GSH↑,
2213- SK,    Shikonin attenuates cerebral ischemia/reperfusion injury via inhibiting NOD2/RIP2/NF-κB-mediated microglia polarization and neuroinflammation
- in-vivo, Stroke, NA
*neuroP↑, *Inflam↓, *iNOS↓, *TNF-α↓, *IL1β↓, *IL6↓, *ARG1/2↑, *TGF-β↑, *IL10↑, *NF-kB↓, *eff↓,
2212- SK,    Shikonin Exerts an Antileukemia Effect against FLT3-ITD Mutated Acute Myeloid Leukemia Cells via Targeting FLT3 and Its Downstream Pathways
- in-vitro, AML, NA
FLT3↓, NF-kB↓, miR-155↓, Diff↑, TumCG↓,
2210- SK,    Shikonin inhibits the cell viability, adhesion, invasion and migration of the human gastric cancer cell line MGC-803 via the Toll-like receptor 2/nuclear factor-kappa B pathway
- in-vitro, BC, MGC803
TumCA↓, TumCI↓, TumCMig↓, MMP2↓, MMP7↓, TLR2↓, p65↓, NF-kB↓, eff↑, ROS↑,
2209- SK,    Shikonin inhibits tumor invasion via down-regulation of NF-κB-mediated MMP-9 expression in human ACC-M cells
- in-vitro, adrenal, ACC-M
MMP9↓, NF-kB↓, IKKα↓,
2202- SK,    Enhancing Tumor Therapy of Fe(III)-Shikonin Supramolecular Nanomedicine via Triple Ferroptosis Amplification
- in-vitro, Var, NA
Iron↑, Ferroptosis↑, pH↝, H2O2↑, ROS↑, Fenton↑, GSH↓, GPx4↓, lipid-P↑,
2218- SK,    Shikonin Alleviates Endothelial Cell Injury Induced by ox-LDL via AMPK/Nrf2/HO-1 Signaling Pathway
- in-vitro, Nor, HUVECs
*Dose↝, *Apoptosis↓, *Casp3↓, *Bcl-2↑, *Inflam↓, *VCAM-1↓, *ICAM-1↓, *E-sel↓, *ROS↓, *SOD↑, *AMPK↑, *NRF2↑, *HO-1↑, *TNF-α↓, *IL1β↓, *IL6↓,
3051- SK,    Resveratrol mediates its anti-cancer effects by Nrf2 signaling pathway activation
- Review, Var, NA
Nrf1↑, Apoptosis↑, TumCP↓, eff⇅, chemoP↑, eff↑, VCAM-1↓, Hif1a↓,
3045- SK,    Cutting off the fuel supply to calcium pumps in pancreatic cancer cells: role of pyruvate kinase-M2 (PKM2)
- in-vitro, PC, MIA PaCa-2
ECAR↓, Glycolysis↓, ATP↓, PKM2↓, TumCMig↓, Ca+2↑, GlucoseCon↓, lactateProd↓, MMP↓, ROS↑,
3044- SK,    Shikonin Inhibits Non-Small-Cell Lung Cancer H1299 Cell Growth through Survivin Signaling Pathway
- in-vitro, Lung, H1299 - in-vitro, Lung, H460
TumCP↓, survivin↓, TumCCA↓, CDK2↓, CDK4↓, XIAP↓, Casp3↑, Casp9↑, cycD1/CCND1↓, cycE/CCNE↓,
3043- SK,    Shikonin Induces Apoptosis by Inhibiting Phosphorylation of IGF-1 Receptor in Myeloma Cells.
- in-vitro, Melanoma, RPMI-8226
IGF-1↓, Apoptosis↑, TumCCA↑, MMP↓, Casp3↑, P53↑, BAX↑, Mcl-1↓, EGFR↓, Src↑, VEGFR2/KDR/Flk1↓, p‑IGF-1↓, PI3K↓, Akt↓,
3042- SK,    The protective effects of Shikonin on lipopolysaccharide/D -galactosamine-induced acute liver injury via inhibiting MAPK and NF-kB and activating Nrf2/HO-1 signaling pathways
- in-vivo, Nor, NA
*TNF-α↓, *IL1β↓, *IL6↓, *IFN-γ↓, *ALAT↓, *AST↓, *MPO↓, *ROS↓, *JNK↓, *ERK↓, *p38↓, *NF-kB↓, *p‑IKKα↓, *SOD↑, *GSH↑, *HO-1↑, *NRF2↑, *hepatoP↑,
3041- SK,    Promising Nanomedicines of Shikonin for Cancer Therapy
- Review, Var, NA
Glycolysis↓, TAMS↝, BioAv↓, Half-Life↝, P21↑, ERK↓, ROS↑, GSH↓, MMP↓, TrxR↓, MMP13↓, MMP2↓, MMP9↓, SIRT2↑, Hif1a↓, PKM2↓, TumCP↓, TumMeta↓, TumCI↓,
3040- SK,    Pharmacological Properties of Shikonin – A Review of Literature since 2002
- Review, Var, NA - Review, IBD, NA - Review, Stroke, NA
*Half-Life↝, *BioAv↓, *BioAv↑, *BioAv↑, *Inflam↓, *TNF-α↓, *other↑, *MPO↓, *COX2/PTGS2↓, *NF-kB↑, *STAT3↑, *antiOx↑, *ROS↓, *neuroP↑, *SOD↑, *Catalase↑, *GPx↑, *Bcl-2↑, *BAX↓, cardioP↑, AntiCan↑, NF-kB↓, ROS↑, PKM2↓, TumCCA↑, Necroptosis↑, Apoptosis↑, DNAdam↑, MMP↓, Cyt‑c↑, LDH↝,
3046- SK,    Shikonin attenuates lung cancer cell adhesion to extracellular matrix and metastasis by inhibiting integrin β1 expression and the ERK1/2 signaling pathway
- in-vitro, Lung, A549
TumCP↓, TumCI↓, TumCMig↓, p‑ERK↓, ITGB1↓,
3047- SK,    Shikonin suppresses colon cancer cell growth and exerts synergistic effects by regulating ADAM17 and the IL-6/STAT3 signaling pathway
- in-vitro, CRC, HCT116 - in-vitro, CRC, SW48
TumCG↓, p‑STAT3↓, ADAM17↓, Apoptosis↑, Casp3↑, cl‑PARP↑, cycD1/CCND1↓, cycE/CCNE↓, TumCCA↑, JAK1?, p‑JAK1↓, p‑JAK2↓, p‑eIF2α↑, eff↓, ROS↑, IL6↓,
3048- SK,    Shikonin inhibits triple-negative breast cancer-cell metastasis by reversing the epithelial-to-mesenchymal transition via glycogen synthase kinase 3β-regulated suppression of β-catenin signaling
- in-vitro, BC, MDA-MB-231 - in-vitro, BC, 4T1 - in-vitro, Nor, MCF12A - in-vivo, NA, NA
tumCV↓, selectivity↑, EMT↓, TumCMig↓, TumCI↓, E-cadherin↑, N-cadherin↓, Vim↓, Snail↓, β-catenin/ZEB1↓, GSK‐3β↑,
3049- SK,    Shikonin Attenuates Chronic Cerebral Hypoperfusion-Induced Cognitive Impairment by Inhibiting Apoptosis via PTEN/Akt/CREB/BDNF Signaling
- in-vivo, Nor, NA - NA, Stroke, NA
*neuroP↑, *p‑PTEN↓, *p‑Akt↑, *Bcl-2↑, *BAX↓, *cognitive↑, *BDNF↑,
3050- SK,    Systemic administration of Shikonin ameliorates cognitive impairment and neuron damage in NPSLE mice
- in-vivo, Nor, NA
*Inflam↓, *neuroP↑, *cognitive↑,
2469- SK,    Shikonin induces the apoptosis and pyroptosis of EGFR-T790M-mutant drug-resistant non-small cell lung cancer cells via the degradation of cyclooxygenase-2
- in-vitro, Lung, H1975
Apoptosis↑, Pyro↑, Casp↑, cl‑PARP↑, GSDME↑, ROS↑, COX2/PTGS2↓, PDK1 / PDPK1↓, Akt↓, ERK↓, eff↓, eff↓, eff↑,
2470- SK,    PKM2/PDK1 dual-targeted shikonin derivatives restore the sensitivity of EGFR-mutated NSCLC cells to gefitinib by remodeling glucose metabolism
- in-vitro, Lung, H1299
PKM2↓, PDK1 / PDPK1↓, Glycolysis↓,
977- SK,    A novel antiestrogen agent Shikonin inhibits estrogen-dependent gene transcription in human breast cancer cells
- in-vitro, BC, T47D - in-vitro, BC, MDA-MB-231 - in-vitro, BC, MCF7 - in-vitro, Nor, HMEC
TumCG↓, ERα/ESR1↓, selectivity↑, *toxicity↓,
965- SK,    Shikonin suppresses proliferation and induces cell cycle arrest through the inhibition of hypoxia-inducible factor-1α signaling
- in-vitro, CRC, HCT116 - in-vitro, CRC, SW-620
Hif1a↓, ROS↓, mTOR↓, p70S6↓, 4E-BP1↓, eIF2α↓, TumCCA↑, TumCP↓, Half-Life↝,
1050- SK,    Shikonin improves the effectiveness of PD-1 blockade in colorectal cancer by enhancing immunogenicity via Hsp70 upregulation
- in-vitro, Colon, CT26
HSP70/HSPA5↑, ROS↑, PKM2↓,
1073- SK,  Chemo,    Natural Compound Shikonin Is a Novel PAK1 Inhibitor and Enhances Efficacy of Chemotherapy against Pancreatic Cancer Cells
- in-vitro, PC, PANC1 - in-vitro, PC, Bxpc-3
PAK1↓, TumCP↓, Apoptosis↑, ChemoSen↑, ROS↑,
1049- SK,    Shikonin inhibits immune checkpoint PD-L1 expression on macrophage in sepsis by modulating PKM2
- in-vivo, NA, NA
TNF-α↓, IL6↓, IFN-γ↓, IL1β↓, PD-L1↓, p‑PKM2↓,
1280- SK,    Shikonin Induces Apoptotic Cell Death via Regulation of p53 and Nrf2 in AGS Human Stomach Carcinoma Cells
- in-vitro, GC, AGS
ROS↑, Casp3↑, P53↑, NRF2↓,
1281- SK,    Enhancement of NK cells proliferation and function by Shikonin
- in-vivo, Colon, Caco-2
Perforin↑, GranB/GZMB↑, p‑ERK↑, p‑Akt↑, NK cell↑, eff↝,
1284- SK,    Shikonin induces ferroptosis in multiple myeloma via GOT1-mediated ferritinophagy
- in-vitro, Melanoma, RPMI-8226 - in-vitro, Melanoma, U266
Ferroptosis↑, LDH↓, ROS↑, Iron↑, lipid-P↑, ATP↓, HMGB1↓, GPx4↓, MDA↑, SOD↓, GSH↓,
2009- SK,    Necroptosis inhibits autophagy by regulating the formation of RIP3/p62/Keap1 complex in shikonin-induced ROS dependent cell death of human bladder cancer
- in-vitro, Bladder, NA
TumCG↓, selectivity↑, *toxicity∅, Necroptosis↑, ROS↑, p62↑, Keap1↑, *NRF2↑, eff↑,
2008- SK,  Cisplatin,    Enhancement of cisplatin-induced colon cancer cells apoptosis by shikonin, a natural inducer of ROS in vitro and in vivo
- in-vitro, CRC, HCT116 - in-vivo, NA, NA
ChemoSen↑, selectivity↑, i-ROS↑, DNAdam↑, MMP↓, TumCCA↑, eff↓, *toxicity↓,
2007- SK,    Shikonin Directly Targets Mitochondria and Causes Mitochondrial Dysfunction in Cancer Cells
- in-vitro, lymphoma, U937 - in-vitro, BC, MCF7 - in-vitro, BC, SkBr3 - in-vitro, CRC, HCT116 - in-vitro, OS, U2OS - NA, Nor, RPE-1
tumCV↓, selectivity↑, Dose↝, other↑, MMP↓, ROS↑, DNAdam↑, Ca+2↑, Casp9↑, Cyt‑c↑, *toxicity↓,
2010- SK,    Shikonin inhibits gefitinib-resistant non-small cell lung cancer by inhibiting TrxR and activating the EGFR proteasomal degradation pathway
- in-vitro, Lung, H1975 - in-vitro, Lung, H1650 - in-vitro, Nor, CCD19
EGFR↓, selectivity↑, Casp↑, PARP↑, Apoptosis↑, ROS↑, eff↓, selectivity↑,
2011- SK,    Shikonin Attenuates Acetaminophen-Induced Hepatotoxicity by Upregulation of Nrf2 through Akt/GSK3β Signaling
- in-vitro, Nor, HL7702 - in-vivo, Nor, NA
*NRF2↑, *hepatoP↑, *ALAT↓, *AST↓, *MPO↓, *ROS↓, *GSH↑,
1342- SK,    RIP1 and RIP3 contribute to shikonin-induced DNA double-strand breaks in glioma cells via increase of intracellular reactive oxygen species
- in-vitro, GBM, NA - in-vivo, NA, NA
RIP1↑, RIP3↑, DNAdam↑, ROS↑, GSH↓,
1343- SK,    Simple ROS-responsive micelles loaded Shikonin for efficient ovarian cancer targeting therapy by disrupting intracellular redox homeostasis
- in-vitro, Ovarian, A2780S - in-vivo, NA, A2780S
*BioAv↓, ROS↑, GSH↓, TumCG↓,
1344- SK,    Novel multiple apoptotic mechanism of shikonin in human glioma cells
- in-vitro, GBM, U87MG - in-vitro, GBM, Hs683 - in-vitro, GBM, M059K
ROS↑, GSH↓, MMP↓, P53↑, cl‑PARP↑, Catalase↓, SOD1↑, Bcl-2↓, BAX↑, eff↓,
1345- SK,    The Critical Role of Redox Homeostasis in Shikonin-Induced HL-60 Cell Differentiation via Unique Modulation of the Nrf2/ARE Pathway
- in-vitro, AML, HL-60
CD14↑, CD11b↑, ROS↑, GSH↓, GSH/GSSG↓, GPx↑, Catalase↓, Diff↑,
1346- SK,    An Oxidative Stress Mechanism of Shikonin in Human Glioma Cells
- in-vitro, GBM, U87MG - in-vitro, GBM, Hs683
NRF2↓, ROS↑, Apoptosis↑, Cyt‑c↑, GSH↓, MMP↓, P53↑, HO-1⇅,
1312- SK,    Shikonin induces apoptosis through reactive oxygen species/extracellular signal-regulated kinase pathway in osteosarcoma cells
- in-vitro, OS, 143B
ROS↑, p‑ERK↑, Bcl-2↓, cl‑PARP↑, Apoptosis↑, TumCCA↑, Bcl-2↑, proCasp3↓,
5102- SK,  GEM,    Shikonin suppresses tumor growth and synergizes with gemcitabine in a pancreatic cancer xenograft model: Involvement of NF-κB signaling pathway
TumCG↓, ChemoSen↑, NF-kB↓, PCNA↓, Ki-67↓, p‑EGFR↓, ROS↑, TumCCA↑, P53↑, JNK↑, Akt↓,

Showing Research Papers: 7551 to 7600 of 8276
Prev Page 152 of 166 Next

* indicates research on normal cells as opposed to diseased cells
Total Research Paper Matches: 8276

Pathway results for Effect on Cancer / Diseased Cells:


Redox & Oxidative Stress(tgid=1) ⓘ

Catalase↓, 2,   Fenton↑, 1,   Ferroptosis↑, 2,   GPx↑, 1,   GPx4↓, 2,   GSH↓, 8,   GSH↑, 1,   GSH/GSSG↓, 1,   H2O2↑, 1,   HO-1⇅, 1,   Iron↑, 2,   Keap1↑, 1,   lipid-P↑, 2,   MDA↑, 1,   Nrf1↑, 1,   NRF2↓, 2,   PYCR1↓, 1,   ROS↓, 1,   ROS↑, 22,   i-ROS↑, 1,   SOD↓, 1,   SOD1↑, 1,   TrxR↓, 1,  

Mitochondria & Bioenergetics(tgid=3) ⓘ

ATP↓, 2,   MMP↓, 8,   XIAP↓, 1,  

Core Metabolism/Glycolysis(tgid=4) ⓘ

ECAR↓, 1,   GlucoseCon↓, 1,   Glycolysis↓, 3,   lactateProd↓, 1,   LDH↓, 1,   LDH↝, 1,   PDK1 / PDPK1↓, 2,   PKM2↓, 6,   p‑PKM2↓, 1,   SIRT2↑, 1,  

Cell Death(tgid=5) ⓘ

Akt↓, 4,   p‑Akt↑, 1,   Apoptosis↑, 10,   BAX↓, 1,   BAX↑, 2,   Bcl-2↓, 2,   Bcl-2↑, 2,   Casp↑, 2,   Casp3↑, 4,   proCasp3↓, 1,   Casp9↑, 2,   Cyt‑c↑, 3,   Ferroptosis↑, 2,   GranB/GZMB↑, 1,   GSDME↑, 1,   JNK↑, 1,   Mcl-1↓, 1,   Necroptosis↑, 4,   Perforin↑, 1,   Pyro↑, 1,   RIP1↑, 2,   survivin↓, 1,  

Kinase & Signal Transduction(tgid=6) ⓘ

p70S6↓, 1,  

Transcription & Epigenetics(tgid=7) ⓘ

other↑, 1,   tumCV↓, 3,  

Protein Folding & ER Stress(tgid=8) ⓘ

eIF2α↓, 1,   p‑eIF2α↑, 1,   HSP70/HSPA5↑, 1,  

Autophagy & Lysosomes(tgid=9) ⓘ

p62↑, 1,  

DNA Damage & Repair(tgid=10) ⓘ

DNAdam↑, 4,   P53↑, 7,   PARP↑, 1,   cl‑PARP↑, 4,   PCNA↓, 1,  

Cell Cycle & Senescence(tgid=11) ⓘ

CDK2↓, 1,   CDK4↓, 1,   cycD1/CCND1↓, 2,   cycE/CCNE↓, 2,   P21↑, 1,   TumCCA↓, 1,   TumCCA↑, 7,  

Proliferation, Differentiation & Cell State(tgid=12) ⓘ

4E-BP1↓, 1,   Diff↑, 2,   EMT↓, 1,   ERK↓, 2,   p‑ERK↓, 1,   p‑ERK↑, 2,   FLT3↓, 1,   GSK‐3β↑, 1,   IGF-1↓, 1,   p‑IGF-1↓, 1,   mTOR↓, 2,   PI3K↓, 2,   Src↑, 1,   p‑STAT3↓, 1,   TumCG↓, 6,  

Migration(tgid=13) ⓘ

Ca+2↑, 2,   CD11b↑, 1,   E-cadherin↑, 1,   ITGB1↓, 1,   Ki-67↓, 1,   miR-155↓, 1,   MMP13↓, 1,   MMP2↓, 2,   MMP7↓, 1,   MMP9↓, 2,   N-cadherin↓, 1,   PAK1↓, 1,   RIP3↑, 2,   Snail↓, 1,   TumCA↓, 1,   TumCI↓, 4,   TumCMig↓, 4,   TumCP↓, 7,   TumMeta↓, 1,   VCAM-1↓, 1,   Vim↓, 1,   β-catenin/ZEB1↓, 1,  

Angiogenesis & Vasculature(tgid=14) ⓘ

EGFR↓, 2,   p‑EGFR↓, 1,   Hif1a↓, 3,   TAMS↝, 1,   VEGFR2/KDR/Flk1↓, 1,  

Immune & Inflammatory Signaling(tgid=16) ⓘ

CD14↑, 1,   COX2/PTGS2↓, 1,   HMGB1↓, 1,   IFN-γ↓, 1,   IKKα↓, 1,   IL1β↓, 1,   IL6↓, 2,   JAK1?, 1,   p‑JAK1↓, 1,   p‑JAK2↓, 1,   NF-kB↓, 6,   NK cell↑, 1,   p65↓, 1,   PD-L1↓, 1,   TLR2↓, 1,   TNF-α↓, 1,  

Cellular Microenvironment(tgid=17) ⓘ

ADAM17↓, 1,   pH↝, 1,  

Hormonal & Nuclear Receptors(tgid=20) ⓘ

ERα/ESR1↓, 1,  

Drug Metabolism & Resistance(tgid=21) ⓘ

BioAv↓, 1,   ChemoSen↑, 3,   Dose↝, 1,   eff↓, 6,   eff↑, 5,   eff⇅, 1,   eff↝, 1,   Half-Life↝, 2,   selectivity↑, 7,  

Clinical Biomarkers(tgid=22) ⓘ

EGFR↓, 2,   p‑EGFR↓, 1,   ERα/ESR1↓, 1,   IL6↓, 2,   Ki-67↓, 1,   LDH↓, 1,   LDH↝, 1,   PD-L1↓, 1,  

Functional Outcomes(tgid=23) ⓘ

AntiCan↑, 1,   cardioP↑, 1,   chemoP↑, 1,   OS↑, 1,  
Total Targets: 159

Pathway results for Effect on Normal Cells:


Redox & Oxidative Stress(tgid=1) ⓘ

antiOx↑, 3,   Catalase↑, 1,   CYP1A1↑, 1,   GPx↑, 1,   GSH↑, 4,   HO-1↑, 5,   MDA↓, 2,   MPO↓, 3,   NQO1↑, 2,   NRF2↑, 9,   ROS↓, 7,   ROS↑, 1,   SOD↑, 6,   TAC↑, 1,  

Mitochondria & Bioenergetics(tgid=3) ⓘ

MMP↓, 1,  

Core Metabolism/Glycolysis(tgid=4) ⓘ

ALAT↓, 2,   AMPK↑, 1,   CYP2C6↑, 1,   CYP3A2↑, 1,   SIRT1↓, 1,   SIRT1↑, 1,  

Cell Death(tgid=5) ⓘ

AhR↑, 1,   p‑Akt↑, 1,   Apoptosis↓, 1,   BAX↓, 3,   Bcl-2↑, 3,   Casp12↓, 1,   Casp3↓, 1,   Casp3↑, 1,   cl‑Casp3↓, 1,   iNOS↓, 2,   JNK↓, 1,   p38↓, 1,  

Transcription & Epigenetics(tgid=7) ⓘ

other↑, 1,  

Protein Folding & ER Stress(tgid=8) ⓘ

CHOP/DDIT3↓, 1,   ER Stress↓, 1,   GRP78/BiP↓, 1,  

Proliferation, Differentiation & Cell State(tgid=12) ⓘ

ERK↓, 1,   Mst1↓, 1,   PI3K↑, 1,   p‑PTEN↓, 1,   STAT3↑, 1,   TumCG↓, 1,  

Migration(tgid=13) ⓘ

ARG1/2↑, 1,   CYP2D1↑, 1,   E-sel↓, 1,   TGF-β↑, 1,   VCAM-1↓, 1,  

Angiogenesis & Vasculature(tgid=14) ⓘ

NO↓, 1,  

Barriers & Transport(tgid=15) ⓘ

NHE3↑, 1,  

Immune & Inflammatory Signaling(tgid=16) ⓘ

COX2/PTGS2↓, 1,   ICAM-1↓, 1,   IFN-γ↓, 1,   p‑IKKα↓, 1,   IL10↑, 1,   IL1β↓, 3,   IL6↓, 3,   Inflam↓, 5,   NF-kB↓, 2,   NF-kB↑, 1,   TNF-α↓, 5,  

Synaptic & Neurotransmission(tgid=18) ⓘ

BDNF↑, 1,  

Drug Metabolism & Resistance(tgid=21) ⓘ

BioAv↓, 2,   BioAv↑, 2,   CYP1A2↑, 1,   Dose↝, 1,   eff↓, 3,   Half-Life↝, 1,  

Clinical Biomarkers(tgid=22) ⓘ

ALAT↓, 2,   AST↓, 2,   IL6↓, 3,  

Functional Outcomes(tgid=23) ⓘ

cardioP↑, 1,   cognitive↑, 2,   hepatoP↑, 2,   neuroP↑, 5,   RenoP↑, 2,   toxicity↓, 3,   toxicity∅, 1,  
Total Targets: 78

Query results interpretion may depend on "conditions" listed in the research papers.
Such Conditions may include : 
  -low or high Dose
  -format for product, such as nano of lipid formations
  -different cell line effects
  -synergies with other products 
  -if effect was for normal or cancerous cells

Filter Conditions: Pro/AntiFlg:%  IllCat:%  CanType:%  Cells:%  prod#:%  Target#:%  State#:%  Dir#:%
  wNotes=0  sortOrder:rid,rpid

 

Home Page